Literature DB >> 31884476

Global Vascular Risk Score and CAIDE Dementia Risk Score Predict Cognitive Function in the Northern Manhattan Study.

Tatjana Rundek1,2, Hannah Gardener1,2, Anita Seixas Dias Saporta1,2, David A Loewenstein1,2, Ranjan Duara3, Clinton B Wright4, Chuanhui Dong1,2, Bonnie Levin1,2, Mitchell S V Elkind5, Ralph L Sacco1,2.   

Abstract

BACKGROUND: Modifiable vascular risk factors (VRF) have been implicated in cognitive impairment.
OBJECTIVE: We compared the prediction of cognitive performance between the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) dementia risk score, a validated tool to estimate dementia risk using VRF, and the Northern Manhattan Study (NOMAS) global vascular risk score (GVRS), created to predict vascular events.
METHODS: The CAIDE and GVRS scores were calculated based on baseline VRF among 1,290 stroke-free participants in the prospective population-based NOMAS MRI cohort (mean age 64±8 years, 60% women; 66% Hispanic, 17% Black, 15% White; 46% completed high school). Domain-specific Z-scores were derived for episodic and semantic memory, executive function, and processing speed, and averaged to calculate global cognition.
RESULTS: The CAIDE score was associated with worse global cognition at initial assessment (Beta per SD = -0.347, p < 0.0001), and with greater decline over time (Beta per SD = -0.033, p = 0.02). These associations were largely due to age and education, and the association with cognitive decline was not significant after adjusting for age, sex, and education. The GVRS was inversely associated with global cognition at initial testing (Beta per SD = -0.247, p < 0.0001) and greater decline over time (Beta per SD = -0.127, p < 0.0001), which persisted after adjusting for sociodemographics. The associations for both scores with initial cognitive performance were driven by executive function and processing speed, and the GVRS was associated with decline in episodic memory and processing speed.
CONCLUSIONS: The GVRS was a stronger predictor of cognitive decline than the CAIDE in a multi-ethnic urban cohort. The inclusion of glucose and smoking in the GVRS, which are absent in CAIDE, likely explains the better performance of the GVRS.

Entities:  

Keywords:  Cognition; dementia; epidemiology; risk score; vascular risk factors

Mesh:

Substances:

Year:  2020        PMID: 31884476      PMCID: PMC7880168          DOI: 10.3233/JAD-190925

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  37 in total

1.  Cognitive function in patients with peripheral artery disease: a prospective single-center cohort study.

Authors:  I Hutter; L Kovacicova; V Jacomella; M Husmann; R Clemens; B Amann-Vesti
Journal:  Int Angiol       Date:  2014-11-14       Impact factor: 2.789

2.  Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study.

Authors:  Ralph L Sacco; Kishlay Anand; Hye-Seung Lee; Bernadette Boden-Albala; Sally Stabler; Robert Allen; Myunghee C Paik
Journal:  Stroke       Date:  2004-09-02       Impact factor: 7.914

3.  Vascular risk factors and cognitive impairment in a stroke-free cohort.

Authors:  F W Unverzagt; L A McClure; V G Wadley; N S Jenny; R C Go; M Cushman; B M Kissela; B J Kelley; R Kennedy; C S Moy; V Howard; G Howard
Journal:  Neurology       Date:  2011-11-08       Impact factor: 9.910

4.  The protective effect of moderate alcohol consumption on ischemic stroke.

Authors:  R L Sacco; M Elkind; B Boden-Albala; I F Lin; D E Kargman; W A Hauser; S Shea; M C Paik
Journal:  JAMA       Date:  1999-01-06       Impact factor: 56.272

5.  Occupational cognitive requirements and late-life cognitive aging.

Authors:  Lindsay R Pool; Jennifer Weuve; Robert S Wilson; Ute Bültmann; Denis A Evans; Carlos F Mendes de Leon
Journal:  Neurology       Date:  2016-03-16       Impact factor: 9.910

6.  Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk scores.

Authors:  Sara Kaffashian; Aline Dugravot; Alexis Elbaz; Martin J Shipley; Séverine Sabia; Mika Kivimäki; Archana Singh-Manoux
Journal:  Neurology       Date:  2013-04-02       Impact factor: 9.910

7.  Infectious Burden and Cognitive Decline in the Northern Manhattan Study.

Authors:  Clinton B Wright; Hannah Gardener; Chuanhui Dong; Mitsuhiro Yoshita; Charles DeCarli; Ralph L Sacco; Yaakov Stern; Mitchell S V Elkind
Journal:  J Am Geriatr Soc       Date:  2015-08       Impact factor: 5.562

8.  Ankle-Brachial Index but Neither Intima Media Thickness Nor Coronary Artery Calcification is Associated With Mild Cognitive Impairment.

Authors:  Christian Weimar; Angela Winkler; Martha Dlugaj; Nils Lehmann; Frauke Hennig; Marcus Bauer; Knut Kröger; Hagen Kälsch; Amir-Abass Mahabadi; Nico Dragano; Susanne Moebus; Barbara Hoffmann; Karl-Heinz Jöckel; Raimund Erbel
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

9.  Midlife risk score for the prediction of dementia four decades later.

Authors:  Lieza G Exalto; Charles P Quesenberry; Deborah Barnes; Miia Kivipelto; Geert Jan Biessels; Rachel A Whitmer
Journal:  Alzheimers Dement       Date:  2013-09-10       Impact factor: 21.566

10.  Midlife CAIDE dementia risk score and dementia-related brain changes up to 30 years later on magnetic resonance imaging.

Authors:  Miika Vuorinen; Gabriela Spulber; Soheil Damangir; Eini Niskanen; Tiia Ngandu; Hilkka Soininen; Miia Kivipelto; Alina Solomon
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

View more
  2 in total

Review 1.  Vascular Cognitive Impairment (VCI).

Authors:  Tatjana Rundek; Magdalena Tolea; Taylor Ariko; Eric A Fagerli; Christian J Camargo
Journal:  Neurotherapeutics       Date:  2021-12-22       Impact factor: 6.088

2.  Prediction of Cognitive Decline Using Heart Rate Fragmentation Analysis: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Madalena D Costa; Susan Redline; Timothy M Hughes; Susan R Heckbert; Ary L Goldberger
Journal:  Front Aging Neurosci       Date:  2021-08-26       Impact factor: 5.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.